Article
The serotonin receptor 3E variant is a risk factor for female IBS-D.
Journal of molecular medicine (Berlin, Germany) - 1 Nov 2022
Fritz Nikola, Berens Sabrina, Dong Yuanjun, Martínez Cristina, Schmitteckert Stefanie, Houghton Lesley A, Goebel-Stengel Miriam, Wahl Verena, Kabisch Maria, Götze Dorothea, D'Amato Mauro, Zheng Tenghao, Röth Ralph, Mönnikes Hubert, Tesarz Jonas, Engel Felicitas, Gauss Annika, Raithel Martin, Andresen Viola, Keller Jutta, Frieling Thomas, Pehl Christian, Stein-Thöringer Christoph, Clarke Gerard, Kennedy Paul J, Cryan John F, Dinan Timothy G, Quigley Eamonn M M, Spiller Robin, Beltrán Caroll, Madrid Ana María, Torres Verónica, Mayer Emeran A, Sayuk Gregory, Gazouli Maria, Karamanolis George, Bustamante Mariona, Estivil Xavier, Rabionet Raquel, Hoffmann Per, Nöthen Markus M, Heilmann-Heimbach Stefanie, Schmidt Börge, Franke André, Lieb Wolfgang, Herzog Wolfgang, Boeckxstaens Guy, Wouters Mira M, Simrén Magnus, Rappold Gudrun A, Vicario Maria, Santos Javier, Schaefert Rainer, Lorenzo-Bermejo Justo, Niesler Beate
Abstract excerpt
Irritable bowel syndrome (IBS) is a gut-brain disorder of multifactorial origin. Evidence of disturbed serotonergic function in IBS accumulated for the 5-HT3 receptor family. 5-HT3Rs are encoded by HTR3 genes and control GI function, and peristalsis and secretion, in particular. Moreover, 5-HT3R antagonists are beneficial in the treatment of diarrhea predominant IBS (IBS-D). We previously reported on functionally...
Read the complete abstract on PubMed